Karen Anderson, PhD
Cards
About
Titles
Professor of Pharmacology and of Molecular Biophysics and Biochemistry
Co-Leader, Developmental Therapeutics, Yale Cancer Center; Co-Director Therapeutics/Chemotherapy ProgramBiography
Karen S. Anderson is a Professor of Pharmacology and Molecular Biophysics and Biochemistry. She is involved in teaching undergraduates and graduate students about drug discovery and structure-based drug design. She also serves as an undergraduate research mentor and is a fellow at Pierson College at Yale serving as a undergraduate freshman advisor. Dr. Anderson's research utilizes mechanistic enzymology and structure-based drug design. Her work focuses on understanding how enzymes, playing critical roles in such diseases as cancer and infectious diseases, including AIDS, work at a molecular level. She uses that information to develop new drug therapies. She has trained over 50 undergraduates, graduate students, M.D./Ph.D. students and postdoctoral students who have gone on to graduate school and medical school as well as successful careers in academia and industry and who are involved in biomedical research.
Appointments
Pharmacology
ProfessorPrimaryMolecular Biophysics and Biochemistry
ProfessorSecondary
Other Departments & Organizations
- Anderson Lab
- Biochemistry, Quantitative Biology, Biophysics and Structural Biology (BQBS)
- Developmental Therapeutics
- Investigative Medicine Program
- Molecular Biophysics and Biochemistry
- Molecular Medicine, Pharmacology, and Physiology
- Pharmacology
- Primary Faculty
- Structural Biology
- Virology Laboratories
- Yale Cancer Center
- Yale Combined Program in the Biological and Biomedical Sciences (BBS)
- Yale CTAP
- Yale Ventures
- Yale-UPR Integrated HIV Basic and Clinical Sciences Initiative
Education & Training
- Senior Research Specialist
- Biorational Herbicide Design, Monsanto Co. (1989)
- PhD
- Ohio State University (1982)
Research
Overview
Also ongoing are studies to understanding the molecular mechanisms of normal and aberrant protein signaling and the effects of selectively guided anticancer drugs such as Iressa and Gleevec. Important molecular targets include EGFR, HER-2, PDGFRb, and c-kit receptor tyrosine kinases. Another area of focus involves investigating the mechanisms of HIV reverse transcriptase as well as drug resistance and toxicity that may ultimately aid in the design of better therapeutic agents for the treatment of AIDS.
Medical Subject Headings (MeSH)
Academic Achievements and Community Involvement
Links & Media
News
- April 23, 2024
A Better COVID Treatment for the Immunocompromised?
- April 15, 2024
Treatments Found in Translational Science
- July 31, 2023
Researchers Develop a New Way to Classify HPV-Associated Head and Neck Cancers
- July 13, 2021Source: News Wise
Scientists Repurpose Cancer and Seizure Medications to Aid in the Fight against COVID-19
Get In Touch
Contacts
Pharmacology
PO Box 208066, 333 Cedar Street
New Haven, CT 06520-8066
United States
Locations
Department of Pharmacology
Academic Office